Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...
News Medical on MSN4d
The CAR T Veteran: A Journey of Resilience, Remission, and AdvocacyLaurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...
Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...
US Weekly on MSN13d
Dave Coulier’s Cancer Battle in His Own Words: From His Diagnosis to His ‘Constant Fight’Dave Coulier has been open about his battle with cancer since he went public with his diagnosis in November 2024 ...
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...
3don MSN
Tea planter Vishal Mahindra was twice diagnosed with non-Hodgkin's lymphoma, a type of blood cancer that develops in the ...
Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback